ROS1 FUSION GENES: POTENTIAL DRUG TARGETS IN NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Davies, Kurtis D. [1 ]
Le, Anh T. [1 ]
Theodoro, Mariana F. [1 ]
Skokan, Margaret C. [1 ]
Aisner, Dara L. [2 ]
Terracciano, Luigi M. [3 ]
Incarbone, Matteo [4 ]
Roncalli, Massimo [4 ]
Cappuzzo, Federico [5 ]
Camidge, Ross D. [1 ]
Doebele, Robert C. [1 ]
Garcia, Marileila V. [1 ]
机构：
[1] Univ Colorado, Sch Med, Dept Med, Aurora, CO USA
[2] Univ Colorado, Sch Med, Dept Pathol, Boulder, CO 80309 USA
[3] Univ Basel Hosp, Basel, Switzerland
[4] Ist Clin Humanitas, Rozzano, Italy
[5] Livorno Hosp, Livorno, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [41] Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer
    Wang, Wenxian
    Cheng, Guoping
    Zhang, Gu
    Song, Zhengbo
    LUNG CANCER, 2020, 146 : 224 - 229
  • [42] Combining Inhibitors of ALK and ROS1 With Other Agents for the Treatment of Non-Small Cell Lung Cancer
    Shaw, Alice T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 280 - 282
  • [43] ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes
    Joshi, Amit
    Pande, Nikhil
    Noronha, Vanita
    Patil, Vijay
    Kumar, Rajiv
    Chougule, Anuradha
    Trivedi, Vaishakhi
    Janu, Amit
    Mahajan, Abhishek
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2019, 13
  • [44] Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
    Sehgal, Kartik
    Patell, Rushad
    Rangachari, Deepa
    Costa, Daniel B.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S779 - S786
  • [45] Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
    Wang, W-X.
    Xu, C.
    Zhuang, W.
    Tian, Y.
    Xu, J.
    Fang, M.
    Chen, Y.
    Chen, G.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S17 - S17
  • [46] Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients
    Glaser, M.
    Von Levetzow, C.
    Michels, S.
    Nogova, L.
    Katzenmeier, M.
    Wompner, C.
    Schmitz, J.
    Bitter, E.
    Terjung, I.
    Passmann, E.
    Schaufler, D.
    Eisert, A.
    Fischer, R.
    Riedel, R.
    Weber, J. P.
    Hahne, S.
    Merkelbach-Bruse, S.
    Buttner, R.
    Wolf, J.
    Scheffler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S456 - S456
  • [47] Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
    Davies, Kurtis D.
    Mahale, Sakshi
    Astling, David P.
    Aisner, Dara L.
    Le, Anh T.
    Hinz, Trista K.
    Vaishnavi, Aria
    Bunn, Paul A., Jr.
    Heasley, Lynn E.
    Tan, Aik-Choon
    Camidge, D. Ross
    Varella-Garcia, Marileila
    Doebele, Robert C.
    PLOS ONE, 2013, 8 (12):
  • [48] The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer
    DeCaire, Ximena
    Streu, Erin
    ONCOLOGY NURSING FORUM, 2016, 43 (05) : 544 - 547
  • [49] Targeting ROS1 receptor tyrosine kinase gene fusions in non-small cell lung cancer
    Davies, Kurtis D.
    Le, Anh T.
    Skokan, Margaret C.
    Theodoro, Mariana F.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    Doebele, Robert C.
    CANCER RESEARCH, 2012, 72
  • [50] Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions
    Desilets, Antoine
    Repetto, Matteo
    Yang, Soo-Ryum
    Drilon, Alexander
    CANCER, 2025, 131
12345